Poseida Therapeutics’ (PSTX) Buy Rating Reiterated at HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $20.00 target price on the stock.

Poseida Therapeutics Trading Down 14.0 %

Shares of Poseida Therapeutics stock opened at $2.76 on Friday. The company’s 50 day moving average price is $2.81 and its two-hundred day moving average price is $2.92. Poseida Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $4.27. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20.

Hedge Funds Weigh In On Poseida Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of PSTX. Blair William & Co. IL grew its holdings in shares of Poseida Therapeutics by 41.3% during the first quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock worth $3,079,000 after purchasing an additional 282,310 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after acquiring an additional 297,500 shares during the last quarter. Vanguard Group Inc. increased its position in Poseida Therapeutics by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after acquiring an additional 473,746 shares during the period. Public Employees Retirement System of Ohio raised its stake in shares of Poseida Therapeutics by 177.3% during the first quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock valued at $201,000 after acquiring an additional 40,245 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its holdings in shares of Poseida Therapeutics by 280.3% during the first quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock worth $91,000 after purchasing an additional 21,138 shares during the period. Institutional investors and hedge funds own 46.87% of the company’s stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.